References
- Cunliffe WJ, Hall R, Newell DJ, Stevenson CJ. Vitiligo, thyroid disease and autoimmunity. Br J Dermatol 1968;80:135–9.
- Hayashi N, Chi H, Kadono T, Nakagawa H, Ishibashi Y, Ando I. Anti-thyroid antibodies and thyroid functions of vitiligo vulgaris (in Japanese). Nippon Hifuka Gakkai Zasshi 1993;103:1301–5.
- van Linthoudt D, Gabay C, Ott H. Vitiligo and polymyositis. Clin Exp Ftheumatol 1989;7:334–5.
- Fox RI, Saito I. Criteria for diagnosis of Sjogren's syndrome. Rheum Dis Clin North Am 1994;20:391–407.
- Lerner AB. On the etiology of vitiligo and gray hair. Am J Med 1971;51:141–7.
- Koga M, Tango T. Clinical features and course of type A and type B vitiligo. Br J Dermatol 1988;118:223–8.
- Brostoff J, Bor S, Feiwel M. Autoantibodies in patients with viti-ligo. Lancet 1969;26:177–8.
- Betterle C, Caretto A, De Zio A, Pedini B, Veller-Fomasa C, Cecchetto A, et al. Incidence and significance of organ-specific autoimmune disorders (clinical, latent or only autoantibodies) in patients with vitiligo. Dermatologica 1985;171:419–23.
- Grimes PE, Haider RM, Jones C, Chakrabarti SG, Enterline J, Minus HR, et al. Autoantibodies and their clinical significance in a black vitiligo population. Arch Dermatol 1983;119:300–3.
- Naughton GK, Eisinger M, Bystryn JC. Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation. J Invest Dermatol 1983;81:540-2.17.
- Le Poole IC, van den Wijngaard RM, Westerhof W, Das PK. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol 1996;148:1219-28.18.
- Allison JR, Curitis AC. Vitiligo and pernicious anemia. Arch Dermatol 1955;72:407.
- Christianson HB, Dorsey CS, O'Leary PA, Kierland RR. Localized scleroderma. Arch Dermatol 1956;74:629-39.19.
- Lerner AB, Sansing J. Vitiligo and linear scleroderma. Arch Dermatol 1973;108:286–7.
- van den Wijngaard R, Wankowicz-Kalinska A, Le Poole C, Tigges B, Westerhof W, Das P. Local immune response in skin of gener- 20. alized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest 2000;80:1299-309.21.
- Goebels N, Michalis D, Engelhardt M, Huber S, Bender A, Pongratz D, et al. Differential expression of perforin in muscle- infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest 1996;97:2905–10.
- Ogg GS, Rod Dunbar P, Romero P, Chen JL, Cerundolo V. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 1998;188:1203–8.
- Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35–42.
- Dunbar PR, Chen JL, Chao D, Rust N, Teisserenc H, Ogg GS, et al. Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma. J Immunol 1999;162:6959–62.
- Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol 1996;19:81–4.
- Edwards OM, Courtenay-Evans RJ, Galley JM, Hunter J, Tait AD. Changes in cortisol metabolism following rifampicin therapy. Lancet 1974;2(7880):548–51.